High Sensitivity and NPV for BinaxNOW Rapid Antigen Test in Children at a Mass **Testing Site During Prevalent Delta Variant Period**

4	Kristie J. Sun BA ^{*^a} , Mary Jane E. Vaeth BS ^{*^b} , Matthew Robinson MD ^c , Maryam Elhabashy BA ^d , Ishaan
5	Gupta MD ^c , Sophia Purekal MD ^b , E. Adrianne Hammershaimb MD MS ^e , Ria Peralta BS ^{b,f} , Asia
6	Mitchell ^b , Maisha Foyez ^b , J. Kristie Johnson PhD ^g , James R Ficke MD ^h , Yukari C. Manabe MD ^c , James
7	D. Campbell MD MS ^e , Charles W. Callahan DO ^g , Charles F. Locke MD ^c , Melinda Kantsiper MD ⁱ ,
8	CONQUER COVID Consortium**, Zishan K. Siddiqui MD ^c
9	
10	*These authors contributed equally to this work.
11	** CONQUER Covid Consortium authors: Jeffrey Fink MD ⁱ , Henry Michtalik MD MPH MHS ^c , Shaker
12	M. Eid MD MBA ^{c,i} , Lee-Ann Wagner MD ⁱ , Mark Phillips MD PhD ^h
13	
14	
15	Affiliations: ^a Case Western Reserve University School of Medicine, Cleveland, OH, USA; ^b Baltimore
16	Convention Center Field Hospital, Baltimore, MD, USA; ^c Department of Medicine, The Johns Hopkins
17	University School of Medicine, Baltimore, MD, USA; ^d University of Maryland Baltimore County,
18	Baltimore, MD, USA; ^e Center for Vaccine Development and Global Health, Department of Pediatrics,
19	University of Maryland School of Medicine, Baltimore, MD, USA; ^f Nova Southeastern University
20	College Of Osteopathic Medicine, Fort Lauderdale, FL, USA; ^g Department of Pathology, University of
21	Maryland School of Medicine, Baltimore, MD, USA; hDepartment of Orthopedic Surgery, The Johns
22	Hopkins University, Baltimore, MD, USA; ⁱ Division of Hospital Medicine, The Johns Hopkins Bayview
23	Medical Center, Baltimore, MD, USA; ^j Division of Internal Medicine, University of Maryland School of
24	Medicine, Baltimore, MD, USA, ^h Johns Hopkins Community Physicians, Baltimore, MD, USA
25	
26	Keywords: COVID-19, pediatric rapid antigen testing

- 28 Address all correspondence and reprint requests to: Zishan K. Siddiqui, MD, Department of
- 29 Medicine, The Johns Hopkins University, Meyer 8134K, 1800 Orleans St, Baltimore, MD, 21287
- 30 (Telephone: 443 287 3631; Fax: 410 502 0923; E-mail: zsiddiq1@jhu.edu).

31 ABSTRACT

32 SARS-CoV-2 continues to develop new, increasingly infectious variants, such as delta and 33 omicron. Here, we evaluate the efficacy of the Abbott BinaxNOW Rapid Antigen Test against 34 Reverse Transcription Polymerase Chain Reaction ("RT-PCR") in 1054 pediatric participants 35 presenting to a state-owned high-volume Coronavirus Disease 2019 (COVID-19) testing site. 36 During the testing period, the delta variant was predominant. Participants were grouped by self-37 reported COVID-19 exposure and symptom status. RT-PCR results demonstrated an overall 38 prevalence rate of 5.2%. For all participants, the sensitivity of the rapid antigen tests was 92.7% 39 (95% CI 82.4% - 98.0%) and specificity was 98.0% (95% CI 97.0%-98.8%). For symptomatic 40 participants, the sensitivity was 92.3% (95% CI 74.9% - 99.1%), specificity was 96.6% (95% CI 41 93.6% - 98.4%), positive predictive value (PPV) was 72.7% (95% CI 54.5% - 86.7%) and 42 negative predictive value (NPV) was 99.2% (95% CI 98.2% - 100%). Among asymptomatic 43 participants, the sensitivity was 92.6% (95% CI 75.7% - 99.1%), specificity was 98.6% (95% CI 44 97.5% - 99.3%) the PPV was 71.4% (95% CI 53.7% - 85.4%) and the NPV was 99.7% (95% CI 45 99.0% - 100%). Our reported sensitivity and NPV are higher than other pediatric studies, 46 potentially because of higher viral load from the more transmissible delta variant, but specificity and PPV are lower. 47 48 **Importance** The BinaxNOW rapid antigen COVID-19 test had a sensitivity of nearly 92% in 49 both symptomatic and asymptomatic children when performed at a high-throughput setting 50 during the more transmissible delta variant dominant period. The test may play an invaluable

51 role in asymptomatic screening and keeping children safe in school.

52 INTRODUCTION

53 Many U.S. children remain susceptible to SARS-CoV-2 infection. 20 million children under 5 have no option for vaccination.¹ Among the 28 million eligible children aged 5-11, 18% have 54 received at least one dose of the Coronavirus Disease 2019 (COVID-19) vaccine as of December 55 8, 2021.² Similarly, only 51% of 25 million eligible children aged 12-17 years have received two 56 doses of the vaccine.² Quick, accurate, and accessible diagnostic testing for SARS-CoV-2 in 57 58 pediatric populations is critical to keeping children in classrooms, especially given the transmissibility of newer variants (e.g. delta, omicron) among vaccinated individuals.^{3,4} The 59 impact of disrupted in-person learning has been substantial. Students are more behind in 60 61 foundational coursework, with the effect compounded for students with historical racial or socioeconomic disadvantages.⁵ 62

63

64 One strategy to keep children safely in school is with routine testing. Challenges around testing 65 include delayed result reporting, high cost for reverse transcription polymerase chain reaction ("RT-PCR") tests, and access disparities among marginalized populations.⁶ Rapid antigen tests 66 67 offer an attractive alternative with results often returned in 15 minutes, lower cost, and ability to predict patients harboring culturable, infectious virus.⁷ Studies of the accuracy of these tests in 68 69 children are conflicting. Most were conducted before the more aggressive variants like delta became prevalent.^{8,9} We evaluated the real-world characteristics of the Abbott BinaxNOW rapid 70 71 antigen test (Abbott Laboratories, Abbott Park, IL) in children presenting to a high-throughput 72 setting. Our study took place in the context of a high prevalence of the delta variant, between 73 May 7, 2021 and December 6, 2021. The prevalence of the delta variant rapidly increased from

less than 2.5% of COVID-19 cases to more than 99% in Maryland and surrounding states during
 the first month of the study period.¹⁰

76

77 METHODS

78 Study design. This single-center prospective study compared the performance, quantified as

rest sensitivity and specificity, of the BinaxNOW rapid antigen test against the current gold standard

80 of RT-PCR. BinaxNOW is a lateral flow assay that targets the SARS-CoV-2 viral nucleocapsid

81 (N) protein. The RT-PCR assay includes a panel of primer/probe sets targeting the viral N gene.

82 This study was approved by the Johns Hopkins institutional review board.

83

84 Participants and study site. All individuals under 18 years old were offered enrollment from

5/7/2021 - 12/6/2021. Potential enrollees and guardians were given written and verbal

86 information about the study and given the opportunity to opt out of the additional anterior nares

87 swabs for the rapid antigen test. The study site was a high-volume walk-up community collection

site linked to the Baltimore Convention Center Field Hospital.

89

Data collection. Before sample collection, data for demographics, symptoms, and any selfperceived exposure status was collected for each participant. Presence of active COVID-19
symptoms was assessed based on the standard Centers for Disease Control and Prevention
(CDC) symptom checklist.¹¹ Participants who reported at least one symptom were considered
"symptomatic," while those who reported no symptoms were considered "asymptomatic."
Participant exposure status was obtained according to CDC risk stratification. Participants were
asked about living with someone with confirmed or suspected COVID-19; if they had been

within 6 feet of someone with confirmed or suspected COVID-19 for more than 15 minutes; and
if they had any other exposure to anyone with confirmed or suspected COVID-19. Participants
were considered to have had high risk exposures if they lived with or were within 6 feet for more
than 15 minutes of someone with confirmed or suspected COVID-19. Date of symptom onset
and exposure were recorded. Test implementation, education, and training processes have been
previously described.¹²

103

104 **Sample collection.** The rapid antigen and RT-PCR samples were collected sequentially for each 105 participant in the study by medical staff who were trained to perform rapid antigen tests. 106 Manufacturer's guidelines were followed in obtaining and processing rapid antigen samples.¹³ 107 Staff collected bilateral anterior nares swabs first for direct inoculation onto rapid antigen tests 108 followed by additional bilateral anterior nares sample for RT-PCR. A designated, trained reader 109 interpreted and recorded the result on-site for each rapid antigen test 15 minutes after the test was 110 administered per the instructions for use. All samples for RT-PCR were sent to the University of 111 Maryland Pathology Associates-Maryland Genomics reference laboratory (University of 112 Maryland School of Medicine, Baltimore, MD) and processed using a modification of the CDC 113 2019 Novel Coronavirus Real-Time RT-PCR Diagnostic Panel. Individuals for whom the RT-114 PCR or rapid antigen test was deemed indeterminate (control line not interpretable) were 115 excluded from analysis. 116 117 Statistical analysis. Accuracy results (sensitivity, specificity, and positive and negative

118 predictive values [PPV, NPV respectively]) and 95% confidence intervals (CIs) were calculated

119 using the binomial exact method for the rapid antigen test for both symptomatic and

120	asymptomatic populations compared with the RT-PCR gold standard. Accuracy results for
121	symptomatic and asymptomatic group were compared. Two tailed P values were calculated
122	using Fisher's exact test. Similar test accuracy was calculated for exposure groups and age
123	groups. Cycle threshold (C _T) values for PCR-positive tests were summarized and compared for
124	symptomatic and asymptomatic groups. A plot showing the distribution of RT-PCR C_T values
125	was generated for symptomatic and asymptomatic individuals (Figure 1). All statistical analyses
126	were performed using JMP Pro, version 14.0.0, software (SAS Institute, Cary, NC).
127	
128	RESULTS
129	During the testing period, 1054 of 2811 children who were seen for diagnostic testing
130	participated in the study. Among participants, 508 (48.3%) were female, 438 (41.6%) were
131	White, 373 (35.4%) were African American, 105 (9.9%) were Hispanic, and the mean age was
132	8.9 years. Non-participants were similar for gender (female 49.1%, $P = 0.6$), were older (mean
133	9.4 years, $P = 0.001$), and were more often African American (55%, $P < 0.0001$) or Hispanic
134	(15.1%, $P < 0.0001$). Symptomatic status was obtained for 1046 (99.2%) participants, of which
135	756 (72.4%) were asymptomatic. Symptomatic participants were younger (7.8 vs 9.3 years, P $<$
136	0.0001). High risk exposure was reported by 152 (20.1%) asymptomatic and 50 (17.2%)
137	symptomatic participants. The COVID-19 prevalence rate, based on RT-PCR results, was 5.2%
138	(55/1054) overall, 9.0% (26/290) for symptomatic individuals, and 3.6% (27/756) for
139	asymptomatic individuals. For symptomatic participants, 96.2% (275/286) tested within 7 days
140	after symptom onset. The prevalence rate was 20% for symptomatic participants with high-risk
141	exposure and 7.2% for asymptomatic with high-risk exposure (Table 1).
142	

143	Test accuracy. The sensitivity of the rapid antigen tests for all participants was 92.7% (95% CI
144	82.4% - 98.0%) and specificity was 98.0% (95% CI 97.0%-98.8%). Sensitivity was similar for
145	symptomatic participants and asymptomatic participants (92.3% vs. 92.6%) ($P = 1.0$). It was also
146	similar for high-risk exposure groups, both symptomatic (80.0%; 95% CI 44.4% - 97.5%) and
147	asymptomatic (81.8%; 95% CI 48.2% - 97.7%) (Table 2). The specificity for symptomatic
148	participants was 96.6% (95% CI 93.6% - 98.4%) and for asymptomatic participants was 98.6%
149	(95% CI 97.5% - 99.3%). Among symptomatic individuals the PPV was 72.7% (95% CI 54.5% -
150	86.7%) and the NPV was 99.2% (95% CI 98.2% - 100%).). Among asymptomatic individuals
151	the PPV was 71.4% (95% CI 53.7% - 85.4%) and the NPV was 99.7% (95% CI 99.0% - 100%).
152	Mean C_T values were similar for the asymptomatic and symptomatic groups (28.6 vs 27) (P =
153	0.2). The test showed 100% sensitivity at C_T count 30 or below in both the symptomatic and
154	asymptomatic populations (Figure 1).

155

156 DISCUSSION

157 This single center prospective study at a state-owned walk-up testing site showed high 158 sensitivity, specificity, and NPV for the rapid antigen test in both symptomatic and 159 asymptomatic children. The sensitivity was 92.3% in symptomatic participants, and all but one 160 of these 26 RT-PCR positive participants were tested within 7 days of symptom onset. The 161 sensitivity in asymptomatic population was nearly identical at 92.6%, with an NPV of nearly 162 100%. Cycle threshold counts were similar for symptomatic and asymptomatic individuals and 163 rapid tests showed 100% sensitivity in both these groups at C_T count less than 30, which signifies 164 higher viral loads and greater transmissibility. Our point estimate of BinaxNOW rapid antigen 165 test sensitivity in children is above the 80% threshold set by the US Food & Drug Administration

166 (FDA) for Emergency Use Authorization (EUA) for both symptomatic and asymptomatic children.¹⁴ Our results show that rapid antigen tests provide a reliable means to diagnose and 167 168 screen for COVID-19 in children. The near 100% NPVs for both symptomatic and asymptomatic 169 children, including some children with recent high-risk exposures, should provide providers and 170 parents with assurance that a negative rapid antigen test with this product can be trusted. These data also provide support to the use of these tests as part of a "test-to-stay" approach in schools.¹⁵ 171 172 Because our study showed that roughly 30% of positive antigen tests were false positives, it 173 would be prudent to confirm all positive antigen tests with a PCR test. 174 175 Our study shows higher sensitivity and NPV but lower specificity and PPV than other pediatric studies.^{8,9} Differences could be related to higher viral load from prevalent delta variant during 176 177 the study period as most of the prior pediatric studies were conducted before the delta variant became widespread.¹⁶ Additionally, ambient conditions for kit storage and use, variation in 178 179 quality of the test kit between lots, and the skill of our experienced testers may also explain higher sensitivity in our study.¹⁷ 180 181 182 Our study has a few limitations. The results from a single-site with over one-year of experience 183 in high volume testing may not be generalizable to all situations. However, with implementation of best practices, similar accuracy would be expected.¹² Our study enrolled only a small number 184 185 of children with high-risk exposure and the estimates of accuracy had broad confidence interval. 186 However, the results are similar to overall symptomatic and asymptomatic groups. Additionally, 187 three of the four false negative tests in the high-risk exposure group were tested within 3 days of

188 exposure and samples were likely collected too early for detection by a rapid antigen test.

190	Given the short turn-around-time, low cost, and ease of use, this test could play an important role
191	in allowing children to limit absence from school and other activities while in quarantine or
192	awaiting PCR test results especially for asymptomatic children. It may assist in implementing
193	test-to-stay strategies, where exposed school children are allowed to continue uninterrupted in-
194	person learning given frequent testing for one week after exposure. ¹⁸ The higher accuracy
195	reported in our study also underscores the magnitude of missed opportunity in failing to make
196	this important tool widely available to schools. If further studies with the extremely transmissible
197	omicron variant show very high viral load and rapid antigen accuracy, these tests could become
198	one of most valuable tools used to fight current and future COVID-19 variants.
199	

200 Acknowledgements

201

202 Conflict of Interest and Financial Disclosures:

- 203 Dr. Manabe reports institutional grants (to Johns Hopkins) from National Institutes of Health,
- 204 Becton-Dickinson, Centers for Disease Control, and Baltimore City Health Department and
- 205 institutional receipt (to Johns Hopkins) of equipment, materials, drugs, medical writing, gifts or
- 206 other services from Hologic, Becton Dickinson, Roche, Cepheid, and ChemBio.

207

- 208 Dr. Robinson reports institutional grants (to Johns Hopkins) from National Institutes of Health,
- 209 Becton-Dickinson, Centers for Disease Control, and institutional receipt (to Johns Hopkins) of
- 210 equipment, materials, drugs from Becton Dickinson.

211

212 All other authors report no conflicts of interests.

213

Funding: No funding support was received for this study. BinaxNOW test kits were provided by

the Maryland Department of Health, free of cost.

References

- Kates J, Tolbert J, Rouw A. An Update on Vaccine Roll-Out for 5-11 Year-olds in the U.S. Kaiser Family Foundation. Published December 8, 2021. Accessed December 22, 2021. <u>https://www.kff.org/coronavirus-covid-19/issue-brief/an-update-on-vaccine-rollout-for-5-11-year-olds-in-the-u-s/</u>
- Children and COVID-19 Vaccination Trends. American Academy of Pediatrics (AAP). Published December 17, 2021. Accessed December 22, 2021. <u>http://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-covid-19-vaccination-trends/</u>
- Rosenberg ES. New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status — New York, May 3–July 25, 2021. MMWR Morb Mortal Wkly Rep. 2021;70. doi:10.15585/mmwr.mm7034e1
- 4. HKUMed finds Omicron SARS-CoV-2 can infect faster and better than Delta in human bronchus but with less severe infection in lung. Li Ka Shing Faculty of Medicine, The University of Hong Kong (HKUMed). Published December 15, 2021. Accessed December 22, 2021. <u>https://www.med.hku.hk/en/news/press/20211215-omicron-sarscov-2-infection</u>
- 5. Dorn E, Hancock B, Sarakatsannis J, Viruleg E. COVID-19 and education: The lingering effects of unfinished learning. *McKinsey & Company*. Published online July 27, 2021:15.

- Chwe H, Quintana A, Lazer D, et al. The COVID States Project #17: COVID-19 test result times. Published online February 10, 2021. doi:10.31219/osf.io/rz34x
- Pekosz A, Parvu V, Li M, et al. Antigen-Based Testing but Not Real-Time Polymerase Chain Reaction Correlates With Severe Acute Respiratory Syndrome Coronavirus 2 Viral Culture. *Clin Infect Dis Off Publ Infect Dis Soc Am*. Published online January 20, 2021:ciaa1706. doi:10.1093/cid/ciaa1706
- Shaikh N, Friedlander EJ, Tate PJ, et al. Performance of a Rapid SARS-CoV-2 Antigen Detection Assay in Symptomatic Children. *Pediatrics*. doi:10.1542/peds.2021-050832
- Sood N, Shetgiri R, Rodriguez A, et al. Evaluation of the Abbott BinaxNOW rapid antigen test for SARS-CoV-2 infection in children: Implications for screening in a school setting. *PLOS ONE*. 2021;16(4):e0249710. doi:10.1371/journal.pone.0249710
- CDC. COVID Data Tracker. Centers for Disease Control and Prevention. Published March 28, 2020. Accessed September 1, 2021. <u>https://covid.cdc.gov/covid-data-tracker</u>
- 11. Coronavirus Disease 2019 (COVID-19) Symptoms. Centers for Disease Control and Prevention. Published February 22, 2021. Accessed December 22, 2021. https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html

- 12. Siddiqui ZK, Chaudhary M, Robinson ML, et al. Implementation and Accuracy of BinaxNOW Rapid Antigen COVID-19 Test in Asymptomatic and Symptomatic Populations in a High-Volume Self-Referred Testing Site. *Microbiology Spectrum*. Published online December 1, 2021. doi:<u>10.1128/Spectrum.01008-21</u>
- Abbott. BinaxNOW COVID-19 Ag Card. Published online December 2020. Accessed August 16, 2021. <u>https://www.fda.gov/media/141570/download</u>

217


14. Food and Drug Administration. 2021. Antigen template for test developers. Version October 26, 2020. From the Policy for Coronavirus Disease-2019 tests during the public health emergency (revised). https://www.fda.gov/regulatory-information/search-fdaguidance-documents/policy-coronavirus-disease-2019-tests-during-public-healthemergency-revised. Template available at https://www.fda.gov/media/137907/download. Accessed on June 14.


- 15. CDC. Transmission of SARS-CoV-2 in K-12 Schools. Centers for Disease Control and Prevention. Published December 17, 2021. Accessed December 26, 2021.
 <u>https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/transmission_k_12_schools.html</u>
- 16. Bolze, A., Luo, S., White, S., Cirulli, E.T., Wyman, D., Dei Rossi, A., Machado, H., Cassens, T., Jacobs, S., Schiabor Barrett, K.M. and Tanudjaja, F., 2021. SARS-CoV-2

variant Delta rapidly displaced variant Alpha in the United States and led to higher viral loads.

- 17. Li B, Deng A, Li K, et al. Viral infection and transmission in a large, well-traced outbreak caused by the SARS-CoV-2 Delta variant. *medRxiv*. Published online January 1, 2021:2021.07.07.21260122. doi:10.1101/2021.07.07.21260122
- Nemoto N, Dhillon S, Fink S, et al. Evaluation of Test to Stay Strategy on Secondary and Tertiary Transmission of SARS-CoV-2 in K–12 Schools — Lake County, Illinois, August 9–October 29, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(5152). doi:<u>10.15585/mmwr.mm705152e2</u>

Figures





219

*Darker dots represent false negative rapid antigen results

220 Tables

- 221 Table 1. Demographics of Children Presenting for COVID-19 Diagnostic Testing with
- 222 Concurrent RT-PCR and Rapid Antigen Test, Baltimore, 2021

Characteristics	Asymptomatic	Symptomatic		
Female	49.9%	44.2%		
Age	9 (6-12) ^a	7 (4-11) ^a		
Race				
White	40.0%	45.9%		
African American	36.6%	32.5%		
Other	23.4%	23.6%		
Ethnicity				
Hispanic	10.1%	8.9%		

^aData presented as median (interquartile range).

224

225 Table 2. Antigen Test Accuracy Rates Compared to RT-PCR as Reference Standard

Exposure	Positive/Total (%)			
Group	RT-PCR	Rapid Antigen Test*	Sensitivity N (%) [95% CI]	Specificity N (%) [95% CI]
Overall	55/1054 (5.2)	71/1054 (6.7)	51/55 (92.7) [82.4 – 98.0]	979/999 (98.0) [96.9 - 98.8]
Symptomatic [*] - All	26/290 (9.0)	33/290 (11.4)	24/26 (92.3) [74.9 - 99.1]	255/264 (96.6) [93.6 - 98.4]
Symptomatic $- \le 7$ days of symptoms	25/275 (9.1)	32/275 (11.6)	23/25 (92.0) [74.0 - 99.0]	241/250 (96.4) [93.3 - 98.3]
Symptomatic – High Risk Exposure	10/50 (20)	10/50 (20)	8/10 (80.0) [44.4 - 97.5]	38/40 (95.0) [83.1 - 99.4]
Asymptomatic ** - All	27/756 (3.6)	35/756 (4.6)	25/27 (92.6) [75.7 - 99.1]	719/729 (98.6) [97.5 - 99.3]
Asymptomatic – High Risk Exposure	11/152 (7.2)	10/152 (6.6)	9/11 (81.8) [48.2 - 97.7]	140/141 (99.3) [96.1 – 100.0]

- 226 *There were no inconclusive or invalid Rapid antigen results
- 227 ** Symptom status data was missing for 8 participants, including 4 participants with rapid antigen positive results
- 228 RT-PCR= Reverse Transcription Polymerase Chain Reaction
- 229 CI = Confidence Interval